Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 8/20 | 0.33 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9896984 | 1.00 | BACE1 (0.35) | BACE1SSTR4SSTR1S1PR5KDM1A | |
| SCHEMBL16224095 | 1.00 | BACE1 (0.35) | BACE1SSTR4SSTR1S1PR5KDM1A | |
| SCHEMBL19857404 | 0.85 | KDM1A (0.34) | BACE1SSTR4SSTR1S1PR5KDM1A | |
| SCHEMBL4356106 | 0.82 | KDM1A (0.43) | KDM1AMAOB | |
| SCHEMBL4356105 | 0.82 | KDM1A (0.43) | KDM1AMAOB | |
| SCHEMBL30565037 | 0.82 | S1PR5 (0.33) | BACE1S1PR5KDM1AMAOB | |
| SCHEMBL14631539 | 0.80 | BACE1 (0.38) | BACE1SSTR4KDM1AMAOB | |
| SCHEMBL9896637 | 0.80 | BACE1 (0.34) | BACE1 | |
| SCHEMBL9897710 | 0.80 | BACE1 (0.34) | BACE1 | |
| SCHEMBL9898143 | 0.80 | BACE1 (0.34) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376442-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2016-06-28 | — | — | US | disclosed |
| US-20150073001-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-8927557-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| EP-2470536-B1 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE12, PDE4A | BACE1 2397/4885SSTR4 1201/4885SSTR1 2283/4885 |
| US-20150073001-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | PDE12, PDE5A, PDE4A | BACE1 3953/4885SSTR4 1650/4885SSTR1 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.